Skip to content

A study of prognosis and pathological features of NSCLC patients after neo-adjuvant therapy

A study of prognosis and pathological features of NSCLC patients after neo-adjuvant therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600129364
Enrollment
Unknown
Registered
2026-08-04
Start date
2026-08-04
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

observed cohort:None

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Pathologically confirmed as NSCLC (including major subtypes like adenocarcinoma and squamous cell carcinoma). 2. Receiving standard neoadjuvant treatment (chemotherapy, immunotherapy, or a combination). 3. Completed radical lung cancer surgery (R0). 4. Have complete postoperative pathology reports and follow-up data. 5. Age >= 18 years.

Exclusion criteria

Exclusion criteria: 1. Having other malignant tumors at the same time; 2. Those who received neoadjuvant therapy irregularly or interrupted it; 3. Those who cannot obtain complete pathological data or follow-up information.

Design outcomes

Secondary

MeasureTime frame
Risk prediction model performance based on pathological features (C-index, AUC);

Primary

MeasureTime frame
Overal Survival;disease-free survival (DFS);

Countries

China

Contacts

Public ContactGuangjian Zhang

The First Affiliated Hospital of Xi'an Jiaotong University

zgj@xjtufh.edu.cn+86 29 8532 3215

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026